公开(公告)号：EP2593277A2

公开(公告)日：2013-05-22

申请号：EP11807174.5

申请日：2011-07-11

申请人： ADDEX Pharma S.A. ,  Merck Sharp & Dohme Corp.

发明人： BOLEA,Christelle ,  CELANIRE, Sylvain ,  TANG, Lam ,  JONES, Philip ,  LIVERTON, Nigel J. ,  SOLL, Richard ,  DONG, Jinchao ,  LEI, Zhiyu ,  LIU, Fuquing ,  KONG, Yanling ,  JU, Yi ,  ZHANG, Haoyong ,  WEI, Jieping ,  WEI, Qaioxin ,  ZHANG, Mingxiang ,  LUO, Yunfu

IPC分类号： B26B5/00

CPC分类号： C07D513/12 ,  A23L27/2056 ,  A23L33/10 ,  A23V2002/00 ,  A61K9/0019 ,  A61K9/0095 ,  A61K9/06 ,  A61K9/10 ,  A61K9/2059 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/55 ,  A61K45/06 ,  C07D513/04 ,  C07D513/14 ,  A61K2300/00 ,  A23V2200/16 ,  A23V2200/322 ,  A23V2200/328

摘要： The present invention relates to novel compounds of Formula (I), wherein M, A and Y are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors - subtype 4 ("mGluR
4 ") which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR
4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR
4 is involved.